Compass Therapeutics
phase clinical studies summary compass a | Compass Therapeutics
Company
Deck Type
Sector
Industry
Deck date
May 2023
Slide
14 of 40
Similar slides by Compass Therapeutics
See diffirences between slides (animation)
Investor Presentation
February 2023
phase clinical studies summary | Compass Therapeutics
Investor Presentation
May 2022
phase studies clinical summary overall response rate at the efficacious dose clinical benefit rate at the efficacious dose | Compass Therapeutics
Related slides by other companies
Nuvectis Pharma
Investor Presentation
January 2024
phase a ongoing | Nuvectis Pharma
Valneva
IPO
April 2021
for highest dose group in phase | Valneva
Nuvectis Pharma
Investor Presentation
August 2023
phase a expected to begin in | Nuvectis Pharma
Kymera
Results
December 2022
interim safety data summary patients at dose level all patients heavily prior lines solid tumor no no treatment related no aes leading to discontinuation | Kymera
Other recent decks by Compass Therapeutics
See all presentations (6 decks)
Investor Presentation
February 2023
Investor Presentation
January 2023
Investor Presentation
May 2022
Investor Presentation
May 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights